JCO oncology practice
Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.
Berenice Collineau, Cecile Bannier-Braticevic, Julia Gilhodes, Céline Delaunay, Elika Loir, Louis Tassy, Philippe Rochigneux, Damien Bruyat, Franck Espinosa, Christophe Manceau, Christelle de la Fouchardière, Emmanuel Mitry, Brice Chanez
Published: 202510.1200/OP-25-00358
Abstract
PURPOSE: For elderly patients with pancreatic ductal adenocarcinoma (PDAC), FOLFIRINOX (FFX) is often contraindicated due to frequent grade III adverse events (AEs) limiting available data on this population. MATERIALS AND METHODS: This retrospective…
Preview only. Read the full abstract at the source